Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?
Braune S, Bergmann A, Bezlyak V, Adlard N. Braune S, et al. Among authors: adlard n. J Cent Nerv Syst Dis. 2022 Aug 4;14:11795735221115912. doi: 10.1177/11795735221115912. eCollection 2022. J Cent Nerv Syst Dis. 2022. PMID: 35958354 Free PMC article.
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers.
Forsberg L, Spelman T, Klyve P, Manouchehrinia A, Ramanujam R, Mouresan E, Drahota J, Horakova D, Joensen H, Pontieri L, Magyari M, Ellenberger D, Stahmann A, Rodgers J, Witts J, Middleton R, Nicholas R, Bezlyak V, Adlard N, Hach T, Lines C, Vukusic S, Soilu-Hänninen M, van der Walt A, Butzkueven H, Iaffaldano P, Trojano M, Glaser A, Hillert J; SPMS Research Collaboration Network. Forsberg L, et al. Among authors: adlard n. Mult Scler J Exp Transl Clin. 2023 Feb 16;9(1):20552173231153557. doi: 10.1177/20552173231153557. eCollection 2023 Jan-Mar. Mult Scler J Exp Transl Clin. 2023. PMID: 36816812 Free PMC article.
The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis.
Samjoo IA, Worthington E, Haltner A, Cameron C, Nicholas R, Dahlke F, Adlard N. Samjoo IA, et al. Among authors: adlard n. Curr Med Res Opin. 2020 Jul;36(7):1145-1156. doi: 10.1080/03007995.2020.1747998. Epub 2020 Apr 14. Curr Med Res Opin. 2020. PMID: 32216597
Efficacy classification of modern therapies in multiple sclerosis.
Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Häring DA, Stoneman D, Klotz L, Adlard N. Samjoo IA, et al. Among authors: adlard n. J Comp Eff Res. 2021 Apr;10(6):495-507. doi: 10.2217/cer-2020-0267. Epub 2021 Feb 23. J Comp Eff Res. 2021. PMID: 33620251 Free article.
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.
Schur N, Gudala K, Vudumula U, Vadapalle S, Bhadhuri A, Casanova A, Adlard N, Schwenkglenks M. Schur N, et al. Among authors: adlard n. Pharmacoeconomics. 2021 May;39(5):563-577. doi: 10.1007/s40273-021-01023-8. Epub 2021 Apr 1. Pharmacoeconomics. 2021. PMID: 33791945 Free PMC article. Clinical Trial.
Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany.
Koeditz D, Frensch J, Bierbaum M, Ness NH, Ettle B, Vudumula U, Gudala K, Adlard N, Tiwari S, Ziemssen T. Koeditz D, et al. Among authors: adlard n. Mult Scler J Exp Transl Clin. 2022 Mar 29;8(1):20552173221085741. doi: 10.1177/20552173221085741. eCollection 2022 Jan-Mar. Mult Scler J Exp Transl Clin. 2022. PMID: 35371535 Free PMC article.
Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Samjoo IA, Klotz L, Giovannoni G, Drudge C, Haltner A, Worthington E, Zhao M, Brennan R, Häring DA, Cameron C, Adlard N. Samjoo IA, et al. Among authors: adlard n. Mult Scler Relat Disord. 2022 Oct;66:104031. doi: 10.1016/j.msard.2022.104031. Epub 2022 Jul 4. Mult Scler Relat Disord. 2022. PMID: 35841716
42 results